MX2022010884A - Agentes terapéuticos y conjugados de estos. - Google Patents

Agentes terapéuticos y conjugados de estos.

Info

Publication number
MX2022010884A
MX2022010884A MX2022010884A MX2022010884A MX2022010884A MX 2022010884 A MX2022010884 A MX 2022010884A MX 2022010884 A MX2022010884 A MX 2022010884A MX 2022010884 A MX2022010884 A MX 2022010884A MX 2022010884 A MX2022010884 A MX 2022010884A
Authority
MX
Mexico
Prior art keywords
sup
class
sub
formula
conjugates
Prior art date
Application number
MX2022010884A
Other languages
English (en)
Inventor
Hui Li
Xianfeng Li
Anrong Li
Yuntao Song
Junbao Yang
Original Assignee
Beijing Xuanyi Pharmasciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Xuanyi Pharmasciences Co Ltd filed Critical Beijing Xuanyi Pharmasciences Co Ltd
Publication of MX2022010884A publication Critical patent/MX2022010884A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción proporciona una clase de conjugados con la fórmula general (X), una clase de derivados de agonistas de TLR9, tales como la fórmula (I), (XX) y (XXI), determinados diastereómeros de agonistas de STING, una clase de derivados de agonistas de STING, tales como la fórmula (XXVIV), una clase de compuestos heterocíclicos con la fórmula general (II), una clase de compuestos heterocíclicos con la fórmula general (III), tal como se definen en el presente documento. En el presente documento se definen A1, A2, T, Z1, Z2, Z3, b1 y b2 en la fórmula (X). El conjugado proporciona propiedades únicas que se basan en las propiedades de los agentes terapéuticos que forman parte del conjugado. También se proporcionan métodos de síntesis y uso de compuestos.
MX2022010884A 2020-03-06 2021-03-05 Agentes terapéuticos y conjugados de estos. MX2022010884A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986223P 2020-03-06 2020-03-06
US202063062503P 2020-08-07 2020-08-07
PCT/US2021/021117 WO2021178818A2 (en) 2020-03-06 2021-03-05 Therapeutic agents and conjugates thereof

Publications (1)

Publication Number Publication Date
MX2022010884A true MX2022010884A (es) 2022-12-02

Family

ID=77613835

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010884A MX2022010884A (es) 2020-03-06 2021-03-05 Agentes terapéuticos y conjugados de estos.

Country Status (10)

Country Link
US (1) US20240066133A1 (es)
EP (1) EP4114417A4 (es)
JP (1) JP7885125B2 (es)
KR (1) KR20220150356A (es)
CN (1) CN115427051B (es)
AU (1) AU2021231864A1 (es)
CA (1) CA3169880A1 (es)
MX (1) MX2022010884A (es)
TW (1) TW202144011A (es)
WO (1) WO2021178818A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4653017A1 (en) * 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
IL322523A (en) * 2023-02-28 2025-10-01 Eisai R&D Man Co Ltd Anti-PSMA antibodies, conjugates and methods of use
CN117924253A (zh) * 2023-08-17 2024-04-26 厦门大学 谷氨酸尿素类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物
WO2026035986A1 (en) 2024-08-07 2026-02-12 Bighat Biosciences, Inc. Humanized anti-cdh17 antibodies and use of the same
WO2026044149A2 (en) * 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthesis of drug-linker combinations for antibody-drug conjugates
WO2026043922A1 (en) * 2024-08-21 2026-02-26 Illumina, Inc. Modified nucleotides and related methods for nanopore sequencing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4169944A1 (en) 2014-03-14 2023-04-26 Biomolecular Holdings LLC Process for preparing hybrid immunoglobulin containing non-peptidyl linkage
US20170095573A1 (en) 2014-06-02 2017-04-06 Baylor Research Institute Methods and compositions for treating allergy and inflammatory diseases
US10046046B2 (en) * 2014-06-05 2018-08-14 Victoria Link Limited Amino sphingoglycolipid analogues
US20180296685A1 (en) 2017-04-13 2018-10-18 Tarveda Therapeutics, Inc. Targeted constructs and formulations thereof
TWI808092B (zh) * 2017-08-30 2023-07-11 中國大陸商北京軒義醫藥科技有限公司 作為干擾素基因調節劑之刺激劑的環狀二核苷酸
WO2019051257A2 (en) * 2017-09-11 2019-03-14 Arbutus Biopharma Corporation METHODS OF TREATING HEPATITIS B TYPE INFECTIONS
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
CN110573184B (zh) * 2018-02-09 2025-05-13 俄亥俄州立创新基金会 Rna纳米结构,其制备方法和用途
WO2019170912A1 (en) * 2018-03-09 2019-09-12 Lidds Ab Bioresorbable controlled-release compositions with sting modulating molecules

Also Published As

Publication number Publication date
EP4114417A2 (en) 2023-01-11
JP7885125B2 (ja) 2026-07-06
US20240066133A1 (en) 2024-02-29
CN115427051A (zh) 2022-12-02
CA3169880A1 (en) 2021-09-10
CN115427051B (zh) 2026-05-08
WO2021178818A3 (en) 2021-10-28
WO2021178818A2 (en) 2021-09-10
KR20220150356A (ko) 2022-11-10
TW202144011A (zh) 2021-12-01
JP2023516965A (ja) 2023-04-21
AU2021231864A1 (en) 2022-09-08
EP4114417A4 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
WO2021178818A3 (en) Therapeutic agents and conjugates thereof
CR20220371A (es) Agonistas heterocíclicos de glp-1
MX2023001311A (es) Agonistas heterociclicos de glp-1.
DK1003504T3 (da) Indolderivater og deres anvendelse som PCP-1-antagonister
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
NL300877I2 (nl) obeticholzuur
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
EA200100766A1 (ru) Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
BG106013A (en) New compounds and compositions as protease inhibitors
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
DK1204654T3 (da) Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
RU95106649A (ru) Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция
EA200400073A1 (ru) Пирролопиримидины как ингибиторы протеинкиназы
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
ATE316083T1 (de) Adamantanderivate
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
SE0402762D0 (sv) Indazole sulphonamide derivatives
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
SE0102055D0 (sv) New Compounds
MX2024012470A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel